Last update 08 Nov 2025

KHK-2823

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
KHK 2823, KHK2823
Target
CD123
Action
inhibitors
Mechanism
CD123 inhibitors(Interleukin-3 receptor subunit alpha inhibitors)
Therapeutic Areas
NeoplasmsHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
Acute Myeloid LeukemiaMyelodysplastic SyndromesRefractory acute myeloid leukemia
Originator Organization
Kyowa Kirin Co., Ltd.Kyowa Kirin Co., Ltd.
Active Organization-
Inactive Organization
Kyowa Kirin Co., Ltd.Kyowa Kirin Co., Ltd.Kyowa Kirin, Inc.Kyowa Kirin Pharmaceutical Development Ltd.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with KHK-2823
NCT02181699
/ TerminatedPhase 1
Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
100 Clinical Results associated with KHK-2823
Login to view more data
100 Translational Medicine associated with KHK-2823
Login to view more data
100 Patents (Medical) associated with KHK-2823
Login to view more data
100 Deals associated with KHK-2823
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 1
United Kingdom
Kyowa Kirin, Inc.
01 Jun 2014
Acute Myeloid LeukemiaPhase 1
United Kingdom
Kyowa Kirin Pharmaceutical Development Ltd.
01 Jun 2014
Myelodysplastic SyndromesPhase 1
United Kingdom
Kyowa Kirin Pharmaceutical Development Ltd.
01 Jun 2014
Myelodysplastic SyndromesPhase 1
United Kingdom
Kyowa Kirin, Inc.
01 Jun 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free